HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice

doi:10.3748/wjg.v10.i23.3506

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4020)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

599

HTML

2965

Figures (1-4)

274

Tables (1-1)

182

Sum=4020

Dec 1, 2004 (publication date) through Nov 7, 2024

Times Cited of This Article

Times Cited (44)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Dec 1, 2004; 10(23): 3506-3510
Published online Dec 1, 2004. doi: 10.3748/wjg.v10.i23.3506

HDR-¹⁹²Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice

Yi Chen, Xiao-Lin Wang, Zhi-Ping Yan, Jie-Min Cheng, Jian-Hua Wang, Gao-Quan Gong, Sheng Qian, Jian-Jun Luo, Qing-Xin Liu

Yi Chen, Xiao-Lin Wang, Zhi-Ping Yan, Jie-Min Cheng, Jian-Hua Wang, Gao-Quan Gong, Sheng Qian, Jian-Jun Luo, Qing-Xin Liu, Department of Radiology, Affiliated Zhongshan Hospital, Medical Center of Fudan University, Shanghai 200032, China

Author contributions: All authors contributed equally to the work.

Correspondence to: Dr. Yi Chen, Department of Radiology, Affiliated Zhongshan Hospital, Medical Center of Fudan University, 180 Fenglin Road, Shanghai 200032, China

Telephone: +86-21-64041990 Ext. 2533

Received: January 10, 2004
Revised: January 22, 2004
Accepted: March 24, 2004
Published online: December 1, 2004

Abstract

AIM: To determine the feasibility and safety of intraluminal brachytherapy in treatment of malignant obstructive jaundice (MOJ) and to evaluate the clinical effect of intraluminal brachytherapy on stent patency and patient survival.

METHODS: Thirty-four patients with MOJ were included in this study. Having biliary stent placed, all patients were classified into intraluminal brachytherapy group (group A, n = 14) and control group (group B, n = 20) according to their own choice. Intraluminal brachytherapy regimen included: HDR-¹⁹²Ir was used in the therapy, fractional doses of 4-7 Gy were given every 3-6 d for 3-4 times, and standard points were established at 0.5-1.0 cm. Some patients of both groups received transcatheter arterial chemoembolization (TACE) after stent placement.

RESULTS: In group A, the success rate of intraluminal brachytherapy was 98.0%, RTOG grade 1 acute radiation morbidity occurred in 3 patients, RTOG/EORTC grade 1 late radiation morbidity occurred in 1 patient. Mean stent patency of group A (12.6 mo) was significantly longer than that of group B (8.3 mo) (P < 0.05). There was no significant difference in the mean survival (9.4 mo vs 6.0 mo) between the two groups.

CONCLUSION: HDR-¹⁹²Ir intraluminal brachytherapy is a safe palliative therapy in treating MOJ, and it may prolong stent patency and has the potentiality of extending survival of patients with MOJ.

Keywords: $[Keywords]